Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib

Related Experiment Video

Updated: Apr 19, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Sebastian Gamba1, Peter Camaj, Volker Heinemann

  • 1aDepartment of Medicine III bInstitute of Medical Informatics, Biometry and Epidemiology, University Hospital Grosshadern, Munich cDepartment of Surgery, University Hospital Magdeburg, Magdeburg dGerman Cancer Consortium (DKTK) eGerman Cancer Research Center (DKFZ), Heidelberg, Germany.

Anti-Cancer Drugs
|December 17, 2014
PubMed

Insights

This study reveals that specific KRAS mutations impact afatinib and gefitinib efficacy in colorectal cancer cells. Afatinib demonstrated greater potency than gefitinib by inhibiting key signaling pathways more effectively.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • KRAS mutations are key drivers in colorectal cancer (CRC).
  • Targeted therapies like afatinib and gefitinib inhibit EGFR signaling but their efficacy varies with KRAS mutation status.
  • Understanding these variations is crucial for personalized CRC treatment.

Purpose of the Study:

  • To investigate the differential impact of various KRAS mutations on the efficacy of afatinib and gefitinib in SW48 CRC cells.
  • To compare the effects of these tyrosine kinase inhibitors on cell viability, cell cycle, and apoptosis in isogenic KRAS wild-type and mutant cell lines.
  • To analyze the downstream signaling pathway modulation by afatinib and gefitinib in response to different KRAS mutations.

Main Methods:

  • Utilized isogenic SW48 colorectal cancer cell lines with wild-type and specific KRAS mutations (G12C, G12S, G12D, G13D, G12A).
  • Assessed cell viability and cell cycle progression following treatment with afatinib and gefitinib.
  • Quantified protein levels of phosphorylated/total EGFR, HER-2, HER-3, ERK, and AKT via Western blotting.

Main Results:

  • Afatinib and gefitinib activity was lowest in KRAS G12C/G12S/G12D mutants and highest in G13D/G12A mutants.
  • Afatinib achieved 50% cell viability reduction at lower concentrations (3.0-7.7 μmol/l) compared to gefitinib (5.4-19.5 μmol/l).
  • Afatinib induced apoptosis more effectively than gefitinib and showed greater inhibition of EGFR, HER-2, ERK, and AKT signaling pathways.

Conclusions:

  • Specific KRAS mutations significantly influence afatinib and gefitinib sensitivity in CRC cells.
  • Afatinib exhibits superior potency over gefitinib in SW48 cells, attributed to broader inhibition of EGFR/HER-2 and downstream signaling.
  • These findings highlight the importance of KRAS mutation profiling for guiding targeted therapy selection in colorectal cancer.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K